GlassScriptPhysician profile
John Pearson Redmond
NPI 1417554361
$22,852.78
in general payments reported to CMS, 2019-2025
22 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $148 · 2023: $841 · 2024: $2,077 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Food and Beverage: $5,245 · Travel and Lodging: $2,666 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $14,475.00 |
| Food and Beverage | $5,244.55 |
| Travel and Lodging | $2,666.35 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $16,535.05 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $1,780.73 | 2021-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,096.52 | 2021-2025 | Caplyta |
| Neuronetics, INC. | $889.18 | 2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $485.97 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $355.61 | 2024-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $300.93 | 2023-2025 | Rexulti, Nuedexta |
| Alkermes, INC. | $280.88 | 2023-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $220.88 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $219.99 | 2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $144.89 | 2021-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $81.23 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $79.14 | 2025 | Cobenfy |
| Tris Pharma INC | $69.91 | 2024-2025 | Dyanavel Xr |
| Corium, LLC | $64.74 | 2024-2025 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $59.49 | 2023-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $45.78 | 2025 | Nuplazid |
| Ironshore Pharmaceuticals INC. | $41.16 | 2023 | Jornay Pm |
| Boston Scientific Corporation | $29.41 | 2024-2025 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $27.76 | 2025 | Uzedy |
| Indivior INC. | $24.74 | 2022 | |
| Atricure, INC. | $18.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Redmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.